The REWRITE Study – REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer

In the pivotal RECOURSE trial, trifluridine/tipiracil improved survival outcomes in refractory metastatic colorectal cancer (mCRC), while demonstrating an acceptable toxicity profile. Routine clinical practice evidence is important to support the ongoing value of recently approved medicines. Our objective was to assess the utilisation patterns and real-world effectiveness of trifluridine/tipiracil in previously treated mCRC patients.

Source: Clinical Oncology - July 13, 2023 Category: Radiology Authors: D. Marques, A.-L. Costa, A. Mansinho, A. Quintela, E. Pratas, J. Brito-Silva, J. Fereira-Cruz, J. F élix, J. Rodrigues, M. Mota, R. Teixeira, S. Dâmaso, S. Pinheiro, V. Andreozzi, L. Costa, A. Barros Tags: Original Article Source Type: research